Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study
ABSTRACT Background Although neoadjuvant chemoimmunotherapy has emerged as a promising approach for resectable non‐small cell lung cancer (NSCLC), comparative real‐world data on different PD‐1 inhibitors are limited. This study compared the clinical efficacy, pathological response, survival, and saf...
Saved in:
| Main Authors: | Bo Yan, Xiaoxuan Sun, Yan Sheng, Ran Zhang, Yanjun Su, Yulong Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical outcomes of conversion surgery following neoadjuvant chemoimmunotherapy in potentially resectable stage IIIA/IIIB non-small cell lung
by: Yana Qi, et al.
Published: (2025-05-01) -
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01) -
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
by: Song Guan, et al.
Published: (2025-07-01) -
Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01) -
Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study
by: Ying Liu, et al.
Published: (2023-12-01)